Cagrilintide

Cagrilintide Peptide: Overview & Clinical Context

Cagrilintide is a synthetic amylin analog developed by Novo Nordisk. Amylin, also known as islet amyloid polypeptide (IAPP), is co-secreted with insulin by pancreatic beta cells and plays important roles in post-meal fullness, gastric emptying, and glucagon suppression. Unlike native amylin, cagrilintide is engineered for once-weekly subcutaneous administration, allowing more stable activity and greater practicality in clinical trial protocols. Cagrilintide monotherapy is not yet approved by the FDA, EMA, or TGA.

However, Novo Nordisk submitted an NDA for CagriSema, the fixed combination of cagrilintide and semaglutide, to the FDA in December 2025, with an FDA advisory committee meeting scheduled for July 2026. Practitioners should verify the current regulatory status directly, as the approval picture is actively evolving.

Is Cagrilintide a GLP-1?

Cagrilintide is not a GLP-1 receptor agonist. It acts on amylin receptors, specifically calcitonin receptor/receptor activity-modifying protein (CALCR/RAMP) complexes found in brain regions involved in appetite and satiety, including the hypothalamus, brainstem, and area postrema. This makes cagrilintide mechanistically distinct from semaglutide, liraglutide, or tirzepatide, which act through GLP-1 or incretin-related pathways. Its mechanism is complementary to GLP-1 activity, which is the rationale behind the CagriSema combination program.

How Cagrilintide Works

Cagrilintide works by activating amylin receptor pathways involved in appetite, gastric emptying, and glucagon regulation. These mechanisms are connected to how the body manages food intake, post-meal fullness, and blood glucose response.

Central Appetite Suppression

Cagrilintide activates amylin receptors in the central nervous system, including the brainstem and hypothalamus, thereby engaging satiety and food-reward pathways. Its action is distinct from GLP-1 receptor-mediated satiety, which helps explain why it is being studied alongside semaglutide rather than as an alternative to it.

Gastric Emptying Delay

Cagrilintide slows gastric emptying, which may prolong post-meal fullness and reduce the rate at which nutrients enter the bloodstream. This mechanism is relevant to both weight management and glycaemic control research.

Post-Prandial Glucagon Suppression

Cagrilintide suppresses post-meal glucagon secretion, which may help reduce post-prandial blood glucose excursions by limiting hepatic glucose output. This is especially relevant in type 2 diabetes research, where glucagon dysregulation is part of the metabolic profile.

Once-Weekly Dosing

Cagrilintide has an approximate half-life of seven days, supporting once-weekly subcutaneous dosing in clinical trial protocols. This distinguishes it from pramlintide, an earlier amylin analog requiring more frequent administration.

Cagrilintide Benefits & Weight Loss Data

The potential benefits of cagrilintide are best understood through available Phase 2 and Phase 3 data. All findings should be described as trial-derived and not interpreted as established clinical outcomes.

• Monotherapy Weight Reduction: In a Phase 2 randomized controlled trial (Lau et al., Lancet, 2021), cagrilintide 4.5 mg once weekly was associated with a mean body weight reduction of approximately 10.8% over 26 weeks compared with placebo in adults with overweight or obesity. This represents the primary standalone efficacy signal for cagrilintide and suggests that amylin receptor activation may meaningfully affect appetite and weight reduction.
• CagriSema Combination Data: The combination of cagrilintide and semaglutide, known as CagriSema, has generated strong research interest because the two compounds act through distinct yet complementary pathways. Phase 3 REDEFINE 1 data reported a mean body weight reduction of approximately 20.4% at week 68 for the treatment policy estimand, and 22.7% for the trial product estimand. These figures are from the Phase 3 program and represent the most current available data while the NDA review is ongoing.
• Glycaemic Control in Type 2 Diabetes: Phase 2 findings suggest potential effects on HbA1c and post-meal glucose regulation, consistent with cagrilintide’s glucagon-suppressing and gastric-emptying mechanisms. Cagrilintide does not yet have an approved glycaemic indication, and these findings should be presented as research data rather than clinical guidance.
• Lifestyle Intervention Context: Clinical trial participants typically receive structured lifestyle intervention alongside pharmacological treatment. Weight-reduction outcomes should be interpreted within the trial context, as real-world results may differ depending on adherence, diet, physical activity, and individual metabolic profiles.

Cagrilintide Starting Dose & Administration

All dosing information should be understood as trial-derived rather than approved prescribing guidance. No standardized clinical protocol has been established outside of registered trial settings.

In published Phase 2 trial protocols (Lau et al., Lancet, 2021), the lowest starting dose evaluated was 0.3 mg once weekly, with escalation through 0.6, 1.2, 2.4, and up to 4.5 mg once weekly. Slow dose escalation is used to support gastrointestinal tolerability, as nausea and vomiting are more likely during early dose increases. Combination settings in Phase 3 have evaluated 2.4 mg once weekly. Dose selection varies by study design and participant population, and these figures should not be treated as prescribing guidance.

Cagrilintide is administered by subcutaneous injection, commonly into the abdomen, thigh, or upper arm. Oral or nasal formulations are not part of the main clinical trial pathway. For storage, cagrilintide should be kept at 2–8°C, protected from light, and not frozen. Standard cold-chain handling procedures should be followed in accordance with product documentation and clinical trial requirements.

Cagrilintide Side Effects & Tolerability

The most commonly reported cagrilintide side effects are gastrointestinal, consistent with other appetite-regulating peptides for weight loss therapies. All tolerability data are from Phase 2 and Phase 3 trial settings.

• Gastrointestinal Effects: Nausea, vomiting, and diarrhea are the most frequently reported and are typically dose-dependent, most noticeable during dose escalation. Gradual titration is used in trials to improve tolerability, and symptoms may lessen once a stable maintenance dose is reached.
• Injection Site Reactions: Mild injection site reactions may occur with subcutaneous administration, including redness, tenderness, or temporary discomfort. These are generally consistent with those seen across injectable peptide therapies.
• Cardiovascular Safety: No major cardiovascular safety signal was identified in Phase 2 data. Long-term cardiovascular outcomes are still being assessed through the Phase 3 REDEFINE program, and cardiovascular safety should not be assumed to be fully established.
• Long-Term Safety: The long-term safety profile of cagrilintide remains under investigation. Practitioners should communicate this evidence gap clearly when discussing cagrilintide in research or protocol contexts.

Regulatory & Legal Status

Information current as of June 2026. The regulatory status of CagriSema is actively evolving. Practitioners should verify the current status directly with the relevant authority before discussing or evaluating cagrilintide. 

United States

Cagrilintide monotherapy is not FDA-approved. Novo Nordisk submitted an NDA for CagriSema to the FDA in December 2025, and an FDA advisory committee meeting is scheduled for July 2026. Practitioners should monitor FDA communications and verify the current status before any sourcing or protocol discussion.

European Union

Cagrilintide is not EMA-approved. Regulatory submission is anticipated following completion and review of Phase 3 REDEFINE data. No approved therapeutic pathway currently exists in the EU.

Australia

Cagrilintide is not TGA-approved. Practitioners should confirm the current TGA status before any research planning or patient-facing discussion.

Given these restrictions, Cagrilintide should be approached with caution and only within the limits of applicable research and regulatory frameworks. Licensed professionals evaluating whether to purchase wholesale materials or order Cagrilintide peptide for research reference should confirm current FDA, TGA, WADA, and jurisdiction-specific guidance, review supplier documentation carefully, and avoid any use that conflicts with human-use, compounding, or athletic anti-doping rules.

Cagrilintide and Semaglutide vs. the Field

Vs Semaglutide

Semaglutide is a GLP-1 receptor agonist approved for obesity and type 2 diabetes in several markets, with a robust Phase 3 evidence base. Cagrilintide acts differently, targeting amylin receptors rather than GLP-1 receptors.

As monotherapy, cagrilintide’s Phase 2 weight-reduction data are meaningful, and the CagriSema combination has produced Phase 3 REDEFINE 1 data showing a mean body weight reduction of approximately 20.4% at week 68. The rationale is that the two compounds influence appetite through separate, complementary pathways, potentially producing additive effects when used together.

Vs Tirzepatide

Tirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes and obesity in several markets, with strong Phase 3 weight reduction data as a monotherapy. Cagrilintide differs because it does not act on GLP-1 or GIP receptors. Instead, it activates amylin receptors, which may influence appetite and glucagon regulation through separate pathways.

At present, tirzepatide holds the regulatory advantage as an approved therapy, while cagrilintide monotherapy remains investigational, and CagriSema is under FDA review.

Vs Retatrutide

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, currently in Phase 3 development and having demonstrated strong Phase 2 weight-loss results. Cagrilintide engages a distinct weight-loss pathway through the amylin receptor system, making it mechanistically different from retatrutide despite both being studied in advanced obesity research. No head-to-head data comparing the two compounds is currently available. Practitioners should monitor ongoing trial results before drawing direct conclusions.

For practitioners considering to purchase Cagrilintide, it is good to evaluate it in comparison with other peptides. Doctor Medica’s staff can provide more information on these comparisons, and can guide practitioners on how to source from qualified and legitimate sources.

Where Can Practitioners Buy Cagrilintide Online?

Cagrilintide is available for research purposes to qualified professionals only and is not intended for general consumer use. When evaluating suppliers, practitioners should prioritize those that can provide verifiable purity documentation, LOT number traceability, and a current certificate of analysis for each batch. Doctor Medica supports licensed professionals by offering sourcing guidance and access to relevant documentation.

Practitioners looking to buy cagrilintide from a verified research-grade supplier are encouraged to contact Doctor Medica’s staff directly for guidance and directions.

FAQs

1. What is cagrilintide?

Cagrilintide is a long-acting synthetic amylin analog developed by Novo Nordisk, studied in Phase 3 trials for obesity and type 2 diabetes. Cagrilintide monotherapy is not yet approved, whereas CagriSema, its fixed combination with semaglutide, has been submitted to the FDA for review, with a decision anticipated in 2026.

2. What does cagrilintide do?

Cagrilintide activates amylin receptors involved in appetite regulation, gastric emptying, and post-meal glucagon suppression. These mechanisms may help reduce caloric intake and support weight reduction in clinical trial settings.

3. Is cagrilintide a GLP-1?

No. Cagrilintide is not a GLP-1 receptor agonist. It acts on amylin receptors (CALCR/RAMP complexes), which are distinct from the GLP-1 receptors targeted by semaglutide and similar therapies, making the two mechanisms complementary rather than redundant.

4. What is the cagrilintide starting dose?

Published Phase 2 trial protocols used 0.3 mg once weekly as the lowest starting dose, with escalation through 0.6, 1.2, 2.4, and up to 4.5 mg. These figures are trial-derived and should not be interpreted as approved prescribing guidance.

5. What are the cagrilintide side effects?

The most common side effects reported in trials are nausea, vomiting, and diarrhea, which are typically dose-dependent and most pronounced during dose escalation. Mild injection site reactions may also occur, and long-term safety data are still being evaluated.

6. How do cagrilintide and semaglutide work together?

Cagrilintide and semaglutide target complementary appetite pathways: cagrilintide through amylin receptors and semaglutide through GLP-1 receptors. Phase 3 REDEFINE 1 data reported a mean body weight reduction of approximately 20.4% at week 68 with the CagriSema combination, and the NDA is under FDA review as of June 2026.

7. Is cagrilintide approved?

Cagrilintide monotherapy is not approved by the FDA, EMA, or TGA. An NDA for CagriSema was submitted to the FDA in December 2025, with an advisory committee meeting scheduled for July 2026. Practitioners should verify the current regulatory status with the relevant authority in their jurisdiction.

References

1. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. doi:10.1016/S0140-6736(21)01751-7
2. Aroda VR, Buzzetti R, Dalskov SM, et al. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. Lancet Diabetes Endocrinol. Published online June 7, 2026. doi:10.1016/S2213-8587(26)00126-9
3. D’Ascanio AM, Mullally JA, Frishman WH. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiol Rev. 2024;32(1):83-90. doi:10.1097/CRD.0000000000000513
4. Dutta D, Nagendra L, Harish BG, et al. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian J Endocrinol Metab. 2024;28(5):436-444. doi:10.4103/ijem.ijem_45_24

For licensed medical professionals. This content is for informational purposes only and does not constitute medical advice.